Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. The company's portfolio includes Jornay PM, a central nervous system stimulant prescription medicine that contains methylphenidate HCl for the treatment of attention deficit hyperactivity disorder; Belbuca, a buccal film that contains buprenorphine for severe and persistent pain that requires an extended treatment period; Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone for the management of pain severe enough to require daily; Nucynta ER and Nucynta IR, which are extended-release and immediate-release oral formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.

Collegium Pharmaceutical Inc.

An update from Collegium Pharmaceutical ( ($COLL) ) is now available. On May 14, 2026, Collegium Pharmaceutical, Inc. held its 2026 Annual Meeting ...

Collegium Shareholders Back Board, Pay and Auditor Choices

Barclays analyst Jenna Davidner maintained a Buy rating on Collegium Pharmaceutical today and set a price target of $56.00. Davidner covers the Hea...

Barclays Keeps Their Buy Rating on Collegium Pharmaceutical (COLL)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Collegium Pharmaceutical (COLL) and Sionna Therapeut...

Analysts Are Bullish on These Healthcare Stocks: Collegium Pharmaceutical (COLL), Sionna Therapeutics, Inc. (SION)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Collegium Pharmaceutical (COLL), Myriad Genetics (...

Analysts Have Conflicting Sentiments on These Healthcare Companies: Collegium Pharmaceutical (COLL), Myriad Genetics (MYGN) and Mineralys Therapeutics, Inc. (MLYS)

Current Quarter	$1.48	Next Quarter	$1.83
Current Year	$6.76	Next Year	$5.91
QoQ Growth	+23.6%	YoY Growth	-12.6%
3Y EPS CAGR	+67.2%	Target Price	$54.33
Consensus	Buy	Upside	+60.8%

Current Quarter Rev	N/A	Next Quarter Rev	N/A
Revenue Growth	N/A	YoY Growth	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	COLL	$33.78	-0.85%	283.71K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	COLL	$33.78	-0.9%	283.71K
3
4
5
6

COLL

COLL

EPS Estimates Overview

EPS Historical Trend (5 Years)

Quarterly EPS Estimates

Revenue Analysis

Get Collegium Pharmaceutical Inc. Data in Excel

Get Collegium Pharmaceutical Inc. Data in Excel